

Evan T Hall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2540901/publications.pdf>

Version: 2024-02-01

9
papers

211
citations

1307594

7
h-index

1474206

9
g-index

10
all docs

10
docs citations

10
times ranked

204
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma. <i>Cancer Medicine</i> , 2022, 11, 3106-3114.	2.8	10
2	Neoantigen-specific CD4+ TÂcells in human melanoma have diverse differentiation states and correlate with CD8+ TÂcell, macrophage, and B cell function. <i>Cancer Cell</i> , 2022, 40, 393-409.e9.	16.8	59
3	Perceptions of time spent pursuing cancer care among patients, caregivers, and oncology professionals. <i>Supportive Care in Cancer</i> , 2021, 29, 2493-2500.	2.2	11
4	Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 2037-2048.	1.6	51
5	Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer?. <i>Cancers</i> , 2021, 13, 3415.	3.7	15
6	Immunologic Characteristics of Nonmelanoma Skin Cancers: Implications for Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 398-407.	3.8	29
7	Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center. <i>Cancer Medicine</i> , 2020, 9, 2106-2112.	2.8	28
8	Reducing Head and Neck UV Exposure in Younger Personsâ€”Millennials, Wear a Hat (or Grow Your Hair) Tj ETQq0,0,0 rgBT /Overlock 1	2.2	1
9	Pathogenic Variants in Less Familiar Cancer Susceptibility Genes: What Happens After Genetic Testing?. <i>JCO Precision Oncology</i> , 2018, 2, 1-10.	3.0	7